Biohaven Pharmaceutical Company Ownership | Who Owns Biohaven Pharmaceutical Company?
Biohaven Pharmaceutical Company Ownership Summary
Biohaven Pharmaceutical Company is owned by 90.49% institutional investors, 11.16% insiders. Vanguard group is the largest institutional shareholder, holding 8.91% of BHVN shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.49% of its assets in Biohaven Pharmaceutical Company shares.
BHVN Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Biohaven Pharmaceutical Company | 90.49% | 11.16% | -1.65% |
Sector | Healthcare Stocks | 49.73% | 8.84% | 41.43% |
Industry | Biotech Stocks | 47.04% | 8.74% | 44.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Vanguard group | 7.27M | 8.91% | $252.41M |
Stifel financial | 6.48M | 7.94% | $224.94M |
Blackrock | 6.17M | 7.56% | $214.15M |
Janus henderson group | 5.90M | 7.23% | $204.72M |
Suvretta capital management | 5.20M | 6.37% | $180.46M |
State street | 3.65M | 4.47% | $126.69M |
Price t rowe associates inc /md/ | 3.28M | 4.03% | $114.01M |
Rp management | 2.94M | 3.60% | $101.93M |
Farallon capital management | 2.25M | 2.75% | $78.03M |
Bellevue group | 2.04M | 2.50% | $70.84M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Rp management | 2.94M | 57.00% | $101.93M |
Oracle investment management | 700.45K | 22.68% | $24.31M |
Suvretta capital management | 5.20M | 6.63% | $180.46M |
5am venture management | 469.97K | 3.65% | $16.31M |
Ars investment partners | 940.51K | 3.12% | $32.65M |
Bison wealth | 328.15K | 2.92% | $17.95M |
Redmile group | 1.09M | 2.28% | $37.75M |
First turn management | 366.02K | 2.07% | $12.70M |
Dafna capital management | 218.73K | 1.81% | $7.59M |
Cormorant asset management, lp | 801.96K | 1.61% | $27.84M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Farallon capital management | 2.25M | 0.37% | 1.45M |
Suvretta capital management | 5.20M | 6.63% | 1.20M |
Vanguard group | 7.27M | 0.00% | 962.99K |
Bellevue group | 2.04M | 1.15% | 890.85K |
Norges bank | 780.67K | 0.00% | 780.67K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Darwin global management | - | - | -1.48M |
T. rowe price investment management | - | - | -1.23M |
Point72 asset management | 177.36K | 0.02% | -732.24K |
Marshall wace, llp | 105.57K | 0.00% | -677.72K |
Ghost tree capital | - | - | -490.00K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Norges bank | 780.67K | 0.00% | 780.67K | $27.10M |
Artal group | 306.70K | 0.27% | 306.70K | $10.65M |
Panagora asset management | 200.07K | 0.03% | 200.07K | $6.94M |
Capital fund management | 90.83K | 0.01% | 90.83K | $3.15M |
Fil | 61.86K | 0.00% | 61.86K | $2.15M |
Sold Out
Holder | Change |
---|---|
Financial gravity asset management | -1.00 |
Tfc financial management | -3.00 |
Principal securities | -3.00 |
Gps wealth strategies group | -5.00 |
Systm wealth solutions | -7.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 263 | 11.91% | 85,395,678 | 3.25% | 90 | 1.02% | 133 | -5.00% | 76 | 43.40% |
Jun 30, 2024 | 233 | -11.74% | 82,690,329 | 11.42% | 101 | 1.23% | 139 | 6.11% | 51 | -30.14% |
Mar 31, 2024 | 264 | 14.29% | 74,214,259 | 2.75% | 90 | 0.88% | 131 | -2.24% | 73 | 46.00% |
Dec 31, 2023 | 231 | 17.26% | 72,225,057 | 16.64% | 101 | 1.23% | 134 | 63.41% | 50 | -28.57% |
Sep 30, 2023 | 197 | -3.90% | 61,920,080 | 1.21% | 90 | 1.13% | 82 | -3.53% | 70 | 7.69% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Total Stock Mkt Idx Inv | 2.52M | 2.49% | 87.00K |
BB Biotech AG Ord | 2.04M | 2.15% | - |
Vanguard Small Cap Index | 2.00M | 1.98% | 109.68K |
T. Rowe Price Health Sciences | 1.85M | 1.95% | 12.38K |
iShares Russell 2000 ETF | 1.94M | 1.92% | -4.35K |
Fidelity Select Biotechnology | 1.79M | 1.77% | -26.70K |
SPDR® S&P Biotech ETF | 1.52M | 1.50% | 16.80K |
Vanguard Small Cap Value Index Inv | 1.35M | 1.34% | 70.84K |
Janus Henderson Global Life Sciences D | 1.20M | 1.26% | -829.00 |
Vanguard Institutional Extnd Mkt Idx Tr | 1.24M | 1.23% | 97.67K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Oct 02, 2024 | CHILDS JOHN W | - | Buy | $999.97K |
Oct 02, 2024 | Coric Vlad | Chief Executive Officer | Buy | $999.97K |
Sep 24, 2024 | Bailey Gregory | - | Buy | $220.97K |
Jul 18, 2024 | CHILDS JOHN W | - | Buy | $1.01M |
Jun 17, 2024 | Car Bruce | Chief Scientific Officer | Buy | $1.01M |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q4 | 2 | - |
2024 Q3 | 2 | - |
2024 Q2 | 10 | - |
2024 Q1 | - | - |
2023 Q4 | 6 | 1 |
BHVN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools